The Perioperative and Operative Management of Esophageal and Gastric Cancer

Sung H. Ferlay J. Siegel R.L. et al.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 71: 209-249Machlowska J. Baj J. Sitarz M. et al.

Gastric Cancer : Epidemiology , Risk Factors , Classification , Genomic Characteristics and Treatment Strategies.

Int J Mol Sci. 21: 4012Iriarte F. Su S. Petrov R.v. et al.

Surgical Management of Early Esophageal Cancer.

Surg Clin North Am. 101: 427-441Leake P.A. Cardoso R. Seevaratnam R. et al.

A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer.

Gastric Cancer. 15: 38-47

Esophageal Cancer.

Gastroenterol Clin North Am. 45: 399-412He H. Chen N. Hou Y. et al.

Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis.

Thorac Cancer. 11: 1121

Gastric Cancer Epidemiology.

Gastrointest Endosc Clin North Am. 31: 425-439Trivers K.F. Sabatino S.A. Stewart S.L.

Trends in esophageal cancer incidence by histology, United States, 1998-2003.

Int J Cancer. 123: 1422-1428Avgerinos K.I. Spyrou N. Mantzoros C.S. et al.

Obesity and cancer risk: Emerging biological mechanisms and perspectives.

Metab Clin Exp. 92: 121-135Coleman H.G. Xie S.H. Lagergren J.

The Epidemiology of Esophageal Adenocarcinoma.

Gastroenterology. 154: 390-405

Esophageal Cancer - American Family Physician.

() ()Karimi P. Islami F. Anandasabapathy S. et al.

Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention.

Cancer Epidemiol Biomarkers Prev. https://doi.org/10.1158/1055-9965.EPI-13-1057

Epidemiology of gastric cancer: global trends, risk factors and prevention.

Gastroenterol Rev. 14

The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma.

Acta Pathol Microbiol Scand. 1: 31-49Berlth F. Bollschweiler E. Drebber U. et al.

Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value.

World J Gastroenterol. 20: 5679-5684Rü Diger Siewert J. Feith M. Werner M. et al.

Adenocarcinoma of the Esophagogastric Junction Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients.

Ann Surg. 232: 353-361Shahbaz Sarwar C.M. Luketich J.D. Landreneau R.J. et al.

Esophageal cancer: An update.

Int J Surg. 8: 417-422di Pietro M. Canto M.I. Fitzgerald R.C.

Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.

Gastroenterology. 154: 421-436Graham D.Y. Schwartz J.T. Cain G.D. et al.

Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.

Gastroenterology. 82: 228-231

AJCC Cancer Staging Manual Eighth Edition.

() ()Rice T.W. Ishwaran H. Ferguson M.K. et al.

Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.

J Thorac Oncol. 12: 36-42Betancourt-Cuellar S.L. Benveniste M.F.K. Palacio D.P. et al.

Esophageal Cancer: Tumor-Node-Metastasis Staging.

Radiol Clin North Am. 59: 219-229Krill T. Baliss M. Roark R. et al.

Accuracy of endoscopic ultrasound in esophageal cancer staging.

J Thorac Dis. 11: S1602-S1609Hong S.J. Kim T.J. Nam K.B. et al.

New TNM staging system for esophageal cancer: What chest radiologists need to know.

Radiographics. 34: 1722-1740Chen Z da Zhang P.F. Xi H.Q. et al.

Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review.

Front Med. 8: 744839Van Zoonen M. Van Oijen M.G.H. Van Leeuwen M.S. et al.

Low impact of staging EUS for determining surgical resectability in esophageal cancer.

Surg Endosc. https://doi.org/10.1007/s00464-012-2254-z

Endoscopic options for early stage esophageal cancer.

J Gastrointest Oncol. 6: 20-30Spolverato G. Ejaz A. Kim Y. et al.

Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative.

J Am Coll Surg. 220: 48-56Fairweather M. Jajoo K. Sainani N. et al.

Accuracy of EUS and CT imaging in preoperative gastric cancer staging.

J Surg Oncol. 111: 1016-1020Sarela A.I. Lefkowitz R. Brennan M.F. et al.

Selection of patients with gastric adenocarcinoma for laparoscopic staging.

Am J Surg. 191: 134-138American Joint Comission on Cancer

AJCC Cancer Staging Manual.

in: Amin M.B. Edge S.B. Greene F.L. AJCC cancer staging Manual. 8ht edition. Springer International Publishing, Chicago, IL: 185-202Borggreve A.S. Kingma B.F. Domrachev S.A. et al.

Surgical treatment of esophageal cancer in the era of multimodality management.

Ann N Y Acad Sci, https://doi.org/10.1111/nyas.13677

Transhiatal versus transthoracic esophagectomy for esophageal cancer.

World J Gastroenterol. 16: 3804Omloo J.M.T. Lagarde S.M. Hulscher J.B.F. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.

Ann Surg. 246: 992-1000Hulscher J.B.F. van Sandick J.W. de Boer A.G.E.M. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

N Engl J Med. 347: 1662-1669Johansson J. DeMeester T.R. Hagen J.A. et al.

En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus.

Arch Surg. 139: 627-633Takahashi C. Shridhar R. Huston J. et al.

Comparative outcomes of transthoracic versus transhiatal esophagectomy.

Surgery. 170: 263-270Wei M.T. Zhang Y.C. Deng X.B. et al.

Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis META-ANALYSIS.

World J Gastroenterol. 20: 10183-10192Visser E. Markar S.R. Ruurda J.P. et al.

Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients: A Systematic Review and Meta-analysis.

Ann Surg. 269: 261-268Peyre C.G. Hagen J.A. DeMeester S.R. et al.

Predicting systemic disease in patients with esophageal cancer after esophagectomy a multinational study on the significance of the number of involved lymph nodes.

Ann Surg. 248: 979-984Schandl A. Johar A. Lagergren J. et al.

Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study.

BMJ Open. https://doi.org/10.1136/bmjopen-2016-012624National Comprehensive Cancer Network

Esophageal and Esophagogastric Junction Cancers (Version 2.2022).

() ()

Updates on Management of Gastric Cancer.

Curr Oncol Rep. 21https://doi.org/10.1007/s11912-019-0820-4National Comprehensive Cancer Network

Gastric Cancer (Version 2.2022).

() ()Songun I. Putter H. Kranenbarg E.M.K. et al.

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

Lancet Oncol. 11: 439-449Degiuli M. Reddavid R. Tomatis M. et al.

D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.

Eur J Cancer. 150: 10-22Fujimura T. Nakamura K. Oyama K. et al.

Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer.

Oncol Rep. 22: 509-514Mocellin S. Mcculloch P. Kazi H. et al.

Extent of lymph node dissection for adenocarcinoma of the stomach.

Cochrane Database Syst Rev. 2015https://doi.org/10.1002/14651858.CD001964.PUB4/MEDIA/CDSR/CD001964/IMAGE_N/NCD001964-CMP-002-02.PNGBiere S.S.A.Y. van Berge Henegouwen M.I. Maas K.W. et al.

Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Lancet. 379: 1887-1892Sgourakis G. Gockel I. Radtke A. et al.

Minimally invasive versus open esophagectomy: meta-analysis of outcomes.

Dig Dis Sci. 55: 3031-3040Smithers B.M. Gotley D.C. Martin I. et al.

Comparison of the Outcomes Between Open and Minimally Invasive Esophagectomy.

Ann Surg. 245: 232Sakamoto T. Fujiogi M. Matsui H. et al.

Comparing Perioperative Mortality and Morbidity of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Retrospective Analysis.

Ann Surg. 274: 324-330Yibulayin W. Abulizi S. Lv H. et al.

Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis.

World J Surg Oncol. 14https://doi.org/10.1186/S12957-016-1062-7Straatman J. van der Wielen N. Cuesta M.A. et al.

Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial.

Ann Surg. 266: 232-236van der Sluis P.C. van der Horst S. May A.M. et al.

Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial.

Ann Surg. 269: 621-630Yang Y. Li B. Yi J. et al.

Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: The RAMIE Trial.

Ann Surg. 275: 646-653Huang C. Liu H. Hu Y. et al.

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.

JAMA Surg. 157: 9-17Kim H.H. Han S.U. Kim M.C. et al.

Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial.

JAMA Oncol. 5: 506-513Huscher C.G.S. Mingoli A. Sgarzini G. et al.

Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial.

Ann Surg. 241: 232-237Guerrini G.P. Esposito G. Magistri P. et al.

Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis.

Int J Surg. 82: 210-228Gong E.J. Kim H. Ahn J.Y. et al.

Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.

Gastric Cancer. https://doi.org/10.1007/s10120-016-0679-0

Endoscopic Resection of Gastric Cancer.

Gastrointest Endosc Clin North Am. 31: 563-579Quero G. Fiorillo C. Longo F. et al.

Propensity score-matched comparison of short- and long-term outcomes between surgery and endoscopic submucosal dissection (ESD) for intestinal type early gastric cancer (EGC) of the middle and lower third of the stomach: a European tertiary referral center experience.

Surg Endosc. 35: 2592-2600Choi I.J. Lee J.H. Kim Y il et al.

Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection.

Gastrointest Endosc. 81: 333-341.e1

EMR/ESD: Techniques, Complications, and Evidence.

Curr Gastroenterol Rep. https://doi.org/10.1007/s11894-020-00777-zJapanese Gastric Cancer Association

Japanese gastric cancer treatment guidelines 2018 (5th edition) Preface to the English version.

Gastric Cancer. https://doi.org/10.1007/s10120-020-01042-yPimentel-Nunes P. Dinis-Ribeiro M. Ponchon T. et al.

Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.

Endoscopy. 47: 829-854Wang J. Zhang X.H. Ge J. et al.

Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: A meta-analysis.

World J Gastroenterol. 20: 8282-8287Draganov P.v. Wang A.Y. Othman M.O. et al.

AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States.

Clin Gastroenterol Hepatol. 17: 16-25.e1Ishihara R. Arima M. Iizuka T. et al.

Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer.

Dig Endosc. https://doi.org/10.1111/den.13654

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

World J Gastroenterol. 22: 1114Wagner A.D. Syn N.L.X. Moehler M. et al.

Chemotherapy for advanced gastric cancer.

Cochrane Database Syst Rev. 2017https://doi.org/10.1002/14651858.CD004064.PUB4/MEDIA/CDSR/CD004064/IMAGE_N/NCD004064-CMP-010-06.PNGZhang J.F. Lv L. Zhao S. et al.

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.

Ann Surg Oncol. 29: 3170-3186Bonnot P.E. Piessen G. Kepenekian V. et al.

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.

J Clin Oncol. 37: 2028-2040Granieri S. Bonomi A. Frassini S. et al.

Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials.

Eur J Surg Oncol. 47: 2757-2767Glehen O. Passot G. Villeneuve L. et al.

GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study.

BMC Cancer. 14Koemans W.J. van der Kaaij R.T. Boot H. et al.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).

BMC Cancer. 19https://doi.org/10.1186/S12885-019-5640-2

Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence - Full Text View - ClinicalTrials.gov.

() ()Götze T.O. Piso P. Lorenzen S. et al.

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III “PREVENT”- (FLOT9) trial of the AIO/CAOGI/ACO.

BMC Cancer. 21https://doi.org/10.1186/S12885-021-08872-8Girling D.J. Bancewicz J. Clark P.I. et al.

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

Lancet. 359: 1727-1733Allum W.H. Stenning S.P. Bancewicz J. et al.

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.

J Clin Oncol. 27: 5062-5067Avid D. Elsen P.K. Obert R. et al.

Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer.

N Engl J Med. 339: 1979-1984Gebski V. Burmeister B. Smithers B.M. et al.

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Lancet Oncol. 8: 226-234Cunningham D. Allum W.H. Stenning S.P. et al.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer From the Departments of Medicine (D. Vol 355.; 2006.

() ()Ychou M. Boige V. Pignon J.P. et al.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial.

J Clin Oncol. 29: 1715-1721Al-Batran S.E. Homann N. Pauligk C. et al.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet. 393: 1948-1957Macdonald J.S. Benedetti J. Smalley S. et al.

Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).

Am J Clin Oncol. 27: 4515van Hagen P. Hulshof M.C.C.M. van Lanschot JJB et al.

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer.

N Engl J Med. 366: 2074-2084Eyck B.M. van Lanschot JJB Hulshof M.C.C.M. et al.

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.

J Clin Oncol. 39: 1995-2004Cats A. Jansen E.P.M. van Grieken N.C.T. et al.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Lancet Oncol. 19: 616-628Slagter A.E. Jansen E.P.M. van Laarhoven H.W.M. et al.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

BMC Cancer. 18https://doi.org/10.1186/S12885-018-4770-2Lee J. Lim D.H. Kim S. et al.

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

J Clin Oncol. 30: 268-273Park S.H. Lim D.H. Sohn T.S. et al.

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.

Ann Oncol. 32: 368-374Leong T. Smithers B.M. Michael M. et al.

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

BMC Cancer. 15Leong T. Smithers B.M. Haustermans K. et al.

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.

Ann Surg Oncol. 24: 2252-2258Hoeppner J. Lordick F. Brunner T. et al.

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

BMC Cancer. 16https://doi.org/10.1186/S12885-016-2564-YReynolds J.v. Preston S.R. O’Neill B. et al.

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).

BMC Cancer. 17https://doi.org/10.1186/S12885-017-3386-2

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Ann Oncol. 19: 1523-1529Gerson J.N. Skariah S. Denlinger C.S. et al.

Perspectives of HER2-targeting in gastric and esophageal cancer.

Expert Opin Investig Drugs. 26: 531-540Bang Y.J. van Cutsem E. Feyereislova A. et al.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lancet. 376: 687-697Safran H.P. Winter K. Ilson D.H. et al.

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.

Lancet Oncol. 23: 259-269Fuchs C.S. Tomasek J. Yong C.J. et al.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet. 383: 31-39Wilke H. Muro K. van Cutsem E. et al.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Lancet Oncol. 15: 1224-1235Al-Batran S.E. Hofheinz R.D. Schmalenberg H. et al.

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

Am J Clin Oncol. 38: 4501Hofheinz R.D. Haag G.M. Ettrich T.J. et al.

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.

Am J Clin Oncol. 38: 4502Kojima T. Shah M.A. Muro K. et al.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

J Clin Oncol. 38: 4138-4148Chin K. Kato K. Cho B.C. et al.

Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

Am J Clin Oncol. 39: 204Kang Y.K. Boku N. Satoh T. et al.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 390: 2461-2471

留言 (0)

沒有登入
gif